+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Diagnostics - Global Strategic Business Report

  • PDF Icon

    Report

  • 176 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5141013
The global market for Cancer Diagnostics was estimated at US$227.2 Billion in 2023 and is projected to reach US$333.8 Billion by 2030, growing at a CAGR of 5.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Cancer Diagnostics Market - Key Trends and Drivers Summarized

Why Is Cancer Diagnostics at the Forefront of Medical Innovation?

Cancer diagnostics is a critical field within healthcare, providing essential tools for the early detection, diagnosis, and monitoring of cancer, significantly improving patient outcomes. The ability to diagnose cancer accurately and at an early stage can make a tremendous difference in treatment success rates and survival. Over the years, cancer diagnostics has evolved from basic imaging techniques to highly sophisticated molecular and genetic testing, enabling the identification of specific cancer types, their progression, and genetic mutations that may influence treatment decisions. The integration of various diagnostic technologies, such as biopsy, blood tests, imaging modalities (like MRI and CT scans), and genomic profiling, provides clinicians with a comprehensive view of a patient's cancer. Moreover, advancements in liquid biopsy and next-generation sequencing (NGS) have transformed how early-stage cancer is detected and monitored. As the field advances, cancer diagnostics is becoming more precise and personalized, playing a crucial role in shaping treatment strategies and improving patient survival rates.

How Are Technological Innovations Driving Cancer Diagnostics?

The rapid pace of technological innovation is profoundly reshaping the cancer diagnostics landscape, bringing forth new tools and methodologies that allow for more accurate and earlier detection. One of the most significant developments has been the rise of genomic and molecular diagnostics, which provide insights into the genetic mutations driving cancer growth. Next-generation sequencing (NGS) enables the comprehensive analysis of a patient's genetic profile, helping clinicians tailor treatments to the individual's unique cancer characteristics, making personalized medicine a reality. Liquid biopsy, another cutting-edge advancement, allows for the detection of cancer through a simple blood test, offering a less invasive and faster alternative to traditional tissue biopsies. This technology is not only useful for early detection but also for monitoring cancer progression and treatment efficacy. Artificial intelligence (AI) and machine learning are also making their mark by enhancing imaging technologies, improving the accuracy of cancer screening, and allowing for the interpretation of complex datasets at an unprecedented speed. These innovations are streamlining diagnostic processes, enabling earlier detection, and facilitating better patient outcomes through more precise, individualized treatment approaches.

What Are the Emerging Trends and Challenges in Cancer Diagnostics?

Several key trends are currently shaping the cancer diagnostics market, each influencing how cancer is detected and managed. A major trend is the increasing demand for non-invasive diagnostics, such as liquid biopsy and advanced imaging techniques, which minimize patient discomfort and reduce the time needed to obtain results. This shift towards minimally invasive methods is gaining traction as patients and healthcare providers alike look for safer and more convenient options. Another trend is the growing emphasis on early detection, driven by rising awareness of cancer screening's life-saving potential. Screening programs for cancers such as breast, colorectal, and lung have expanded, leading to increased demand for diagnostic tools that can catch cancer at its earliest stages. However, the field faces several challenges as well. The complexity and cost of advanced diagnostic technologies can pose barriers to widespread adoption, particularly in low- and middle-income regions. Moreover, the sheer volume of data generated by genomic testing and imaging requires sophisticated data management and analysis systems, posing a challenge for healthcare providers in terms of integration and interpretation. Despite these challenges, the trend towards personalized medicine and early detection continues to propel innovation in cancer diagnostics.

What Factors Are Fueling the Expansion of the Cancer Diagnostics Market?

The growth in the cancer diagnostics market is driven by several factors, primarily advances in technology, rising cancer prevalence, and the increasing emphasis on early detection and personalized treatment. One of the key growth drivers is the surge in demand for molecular diagnostics, particularly next-generation sequencing (NGS) and liquid biopsy technologies, which provide more accurate and less invasive options for detecting cancer. The growing adoption of personalized medicine, where treatment plans are tailored to the individual's genetic profile, has also spurred demand for diagnostic tools that can identify specific biomarkers and mutations. Additionally, the rising global incidence of cancer, driven by factors such as aging populations and lifestyle-related risk factors, is increasing the need for diagnostic solutions that can detect cancer early and improve patient outcomes. Government initiatives and healthcare policies promoting regular cancer screenings have also fueled the demand for diagnostic tests, particularly in developed markets. Another significant factor driving market growth is the integration of artificial intelligence and machine learning into diagnostic imaging and data analysis, which enhances the accuracy and speed of cancer detection. These factors, combined with the continued expansion of diagnostic capabilities into emerging markets, are expected to sustain the rapid growth of the cancer diagnostics industry in the years to come.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Breast Application segment, which is expected to reach US$56.4 Billion by 2030 with a CAGR of a 5.9%. The Lung Application segment is also set to grow at 6.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $60.2 Billion in 2023, and China, forecasted to grow at an impressive 8.4% CAGR to reach $75.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Cancer Diagnostics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer Diagnostics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Cancer Diagnostics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott Diagnostics, Abbott Laboratories, Agilent Technologies, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 47 Featured):

  • Abbott Diagnostics
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Ambry Genetics Corporation
  • Applied Imaging
  • AstraZeneca PLC
  • AutoGenomics, Inc.
  • BARD, A Becton, Dickinson Company
  • Bayer AG
  • Becton, Dickinson and Company
  • BioCurex, Inc.
  • bioMeriux SA
  • Celara Diagnostics
  • Diagnostic Products Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Genoptix, Inc.
  • GlaxoSmithKline PLC
  • Hologic, Inc.
  • Illumina, Inc.
  • Pfizer, Inc.
  • Philips Healthcare
  • QIAGEN GmbH
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Cancer Globally Spurs Growth in Demand for Cancer Diagnostics
  • Technological Advancements in Genomics Throw the Spotlight on Precision Cancer Diagnostics
  • Growth in Personalized Medicine Expands Addressable Market Opportunity for Advanced Diagnostic Tools
  • Increasing Focus on Early Detection Propels Adoption of Non-Invasive Cancer Diagnostic Techniques
  • Growing Use of Liquid Biopsy Accelerates Demand for Minimal Invasive Cancer Diagnostic Methods
  • Expanding Applications of Biomarker Testing Sustain Growth in Cancer Diagnostics
  • Innovations in Imaging and Screening Generate New Opportunities for Early Cancer Detection
  • Shift toward Point-of-Care Diagnostics Strengthens Demand for Portable Cancer Diagnostic Tools
  • Growth in Molecular Diagnostics Expands Market Potential for Targeted Cancer Screening
  • Growing Use of Next-Generation Sequencing Accelerates Precision Cancer Diagnostics Adoption
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Breast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Breast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Breast by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Colorectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Colorectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Colorectal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Skin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Skin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Skin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Prostate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Prostate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Prostate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Ovarian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Ovarian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Ovarian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 30: World Historic Review for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: World 16-Year Perspective for Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Laboratory Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: World Historic Review for Laboratory Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: World 16-Year Perspective for Laboratory Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 35: World Recent Past, Current & Future Analysis for Genetic Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 36: World Historic Review for Genetic Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: World 16-Year Perspective for Genetic Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 38: World Recent Past, Current & Future Analysis for Endoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 39: World Historic Review for Endoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: World 16-Year Perspective for Endoscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 41: World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 42: World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: World 16-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 44: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 45: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
JAPAN
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
AUSTRALIA
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Diagnostics
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Ambry Genetics Corporation
  • Applied Imaging
  • AstraZeneca PLC
  • AutoGenomics, Inc.
  • BARD, A Becton, Dickinson Company
  • Bayer AG
  • Becton, Dickinson and Company
  • BioCurex, Inc.
  • bioMeriux SA
  • Celara Diagnostics
  • Diagnostic Products Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Genoptix, Inc.
  • GlaxoSmithKline PLC
  • Hologic, Inc.
  • Illumina, Inc.
  • Pfizer, Inc.
  • Philips Healthcare
  • QIAGEN GmbH
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

Table Information